dr. herbst on the unique benefit of targeting the pd-1/pd-l1 pathway in lung cancer
Published 10 years ago • 450 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:13
dr. herbst on targeting pd-1 and pd-l1 in lung cancer
-
1:23
dr. herbst on targeting pd-1 and pd-l1 in lung cancer
-
1:02
dr. herbst on pd-1 inhibitors in lung cancer
-
1:49
dr. herbst on the impact of frontline immunotherapy in lung cancer
-
1:56
dr. herbst on advances of immunotherapy in lung cancer
-
0:58
dr. herbst on immunotherapy in lung cancer
-
1:12
dr. roy herbst on the emergence of immunotherapy in cancer
-
49:05
pediatric autoimmune encephalitis – catherine otten, md
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
1:59
dr. herbst on key immunotherapy findings in nsclc
-
0:58
dr. chandra belani on selecting the best anti pd-l1 agent in lung cancer
-
1:57
targeting pd-1 and pd-l1 for lung cancer therapy
-
1:01
dr. herbst on the international lung cancer congress
-
1:22
dr. herbst on immune resistance in lung cancer
-
1:03
dr. herbst on combination therapies for lung cancer
-
2:41
dr. roy herbst describes the efficacy of immune checkpoint inhibitors
-
1:35
dr. herbst on promising immunotherapy combinations in nsclc
-
2:55
blueprint project update: how comparable are the results of different pd-l1 assays?
-
0:56
pembrolizumab and the significance of pd-l1 for lung cancer